Cabaletta Bio, Inc. (Nasdaq: CABA) is set to present new and updated clinical data on CABA-201, an investigational 4-1BB-containing fully human CD19-CAR T cell therapy, at the American College of Rheumatology (ACR) Convergence 2024. The conference will take place in Washington, D.C., from November 14-19, 2024. The data will highlight CABA-201's potential in treating autoimmune diseases, specifically immune-mediated necrotizing myopathy (IMNM) and systemic lupus erythematosus (SLE).
Oral Presentation Details
An oral presentation titled "Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials" will be delivered by David J. Chang, M.D., M.P.H, FACR, Chief Medical Officer of Cabaletta Bio, on Sunday, November 17, 2024, from 3:30 p.m. to 3:45 p.m. ET.
Poster Presentation Details
A poster presentation titled "Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-Myositis™ and RESET-SLE™ Clinical Trials" will be presented by Daniel Nunez, Ph.D., Director, Computational Biology at Cabaletta Bio, on Saturday, November 16, 2024, from 10:30 a.m. to 12:30 p.m. ET.
About CABA-201
CABA-201 is designed to induce a deep and transient depletion of CD19-positive cells following a single infusion. This approach aims to achieve an "immune system reset," potentially leading to durable remission without the need for chronic therapy in autoimmune disease patients. Cabaletta Bio is currently evaluating CABA-201 across multiple autoimmune conditions, including myositis (idiopathic inflammatory myopathy, or IIM), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), generalized myasthenia gravis (gMG), and pemphigus vulgaris (PV).
Cabaletta Bio is dedicated to the discovery and development of engineered T cell therapies with the potential to provide deep, durable, and potentially curative treatments for autoimmune diseases. The CABA™ platform includes the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201 as the lead candidate, and the CAART (chimeric autoantibody receptor T cells) strategy, with candidates like DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis.
